Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced new dermatology data presented at the European Academy of Dermatology and Venereology (EADV) ...

NEWARK, Del, Aug. 27, 2024 (GLOBE NEWSWIRE) -- As per the latest analysis, the biosimilar and biologics market value is estimated to reach USD 520.9 billion in 2024. Global sales of biosimilar and ...

Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing ...

From the creation of a regulatory pathway for biosimilars in the EU only three biologics experienced EU biosimilar competition until the launch of Remsima/Inflectra in 2013, and none have (as at ...

BENGALURU, India, Aug. 29, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced ...

With more biosimilar options available, we’ve seen a significant uptick in biosimilar market share. For example, Zarxio has captured more than 50% of market share in the Filgrastim market since ...

(MENAFN- GlobeNewsWire - Nasdaq) The Pharmaceutical industry has made significant strides in biosimilars and biologics, offering opportunities for innovation, growth, and enhanced patient access ...

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has secured market entry for its proposed biosimilar to Stelara in Europe, the UK, Canada, and Japan. The company announced today ...

Pharmaceutical companies are making investments in research of therapies that target three different antigen-binding sites. Trispecific antibody research is still in its earliest phases and is focused ...